目前对于不可切除的中晚期肝细胞癌（HCC）患者，采用以TACE、消融术、靶向治疗、免疫治疗和立体定向放射治疗（SBRT）为主的综合治疗，取得明显疗效。近年来，免疫检查点抑制剂（ICI）已经彻底改变了HCC 的治疗，但仍然面临应答率低、治疗抵抗和肿瘤超进展等困境。局部区域介入治疗能够积极改善肿瘤免疫微环境，与免疫治疗联合应用可以通过协同作用提高治疗效果，从而改善HCC 的生存率。尽管其已经取得了一些令人鼓舞的成果，仍有许多亟待解决的问题，包括探索联合治疗的最佳组合方案，如何确定治疗时机和顺序，如何寻找有效预测ICI 治疗反应性的血清学和（或）组织学生物标志物等。目前研究显示免疫治疗联合局部或区域疗法能够提高HCC 免疫治疗的疗效，但鉴于目前几项研究均存在样本量小和回顾性研究的限制，还需要进一步的大样本、前瞻性的临床试验来分析潜在的益处和安全性问题。本综述总结免疫治疗联合局部区域疗法治疗HCC 的研究进展，并对其现状和未来发展进行总结和评价。

At present， comprehensive treatments mainly including TACE， ablation， targeted therapy， immunotherapy and stereotactic body radiotherapy （SBRT） have achieved high efficacy in patients with unresectable advanced hepatocellular carcinoma （HCC）.In recent years， immune checkpoint inhibitor（ICI） has completely revolutionized the treatment of HCC， whereas it still encounters challenges， such as low response rate， treatment resistance and tumor hyperprogression， etc.Locoregional interventional therapy can actively improve the tumor immune microenvironment， and combined application of immunotherapy can enhance efficacy through synergical effect， thereby elevating the survival rate of HCC.Although encouraging achievements have been made， multiple problems remain to be resolved urgently， including exploring the optimal combined regimen， how to determine the timing and sequence of treatment and how to identify serological and/or histological biomarkers that can effectively predict the response of ICI treatment， etc.Current studies have shown that immunotherapy combined with local or regional therapy can improve the efficacy of immunotherapy for HCC.Nevertheless， due to the limitations of small sample size and retrospective study design in several studies， prospective clinical trials with large sample size are required to analyze the potential benefits and evaluate the safety.In this article， the research progress in immunotherapy combined with locoregional therapy for HCC was reviewed， and the current status and future development were summarized and assessed.